Modelling chemotherapy resistance in palliation and failed cure

DOI10.1016/J.JTBI.2008.12.006zbMath1400.92274OpenAlexW2063557699WikidataQ83169071 ScholiaQ83169071MaRDI QIDQ1617549

Helen C. Monro, Eamonn A. Gaffney

Publication date: 8 November 2018

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Full work available at URL: https://ora.ox.ac.uk/objects/uuid:e12082bb-bec6-4135-8754-9d45ca25115a

zbMATH Keywords

mathematical modellingdrug resistancesurvival timeadvanced cancerdrug scheduling

Mathematics Subject Classification ID

Medical applications (general) (92C50)

Related Items (8)

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer ⋮ Tumour-host dynamics under radiotherapy ⋮ Tumor containment: a more general mathematical analysis ⋮ Modeling of drug resistance: Comparison of two hypotheses for slowly proliferating tumors on the example of low‐grade gliomas ⋮ Competition between populations: preventing domination of resistant population using optimal control ⋮ What does not kill a tumour may make it stronger: \textit{in silico} insights into chemotherapeutic drug resistance ⋮ Computational determination of the optimal dose of the cis-platinum to maximize the life time of patients diagnosed with cancer. ⋮ An evolutionary dynamics model for metastatic tumour growth based on public goods games

Cites Work

• The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics
• The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling
• Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis

This page was built for publication: Modelling chemotherapy resistance in palliation and failed cure